Compagnie Lombard Odier SCmA Has $142.48 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Compagnie Lombard Odier SCmA lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 293,760 shares of the medical research company’s stock after purchasing an additional 13,032 shares during the period. Thermo Fisher Scientific makes up about 1.6% of Compagnie Lombard Odier SCmA’s investment portfolio, making the stock its 17th biggest position. Compagnie Lombard Odier SCmA owned approximately 0.08% of Thermo Fisher Scientific worth $142,479,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently bought and sold shares of TMO. Midwest Trust Co lifted its holdings in Thermo Fisher Scientific by 4.1% during the 3rd quarter. Midwest Trust Co now owns 89,198 shares of the medical research company’s stock worth $43,263,000 after buying an additional 3,493 shares in the last quarter. Rockland Trust Co. lifted its stake in shares of Thermo Fisher Scientific by 17.4% during the third quarter. Rockland Trust Co. now owns 63,992 shares of the medical research company’s stock valued at $31,037,000 after acquiring an additional 9,467 shares during the period. Wealthfront Advisers LLC increased its position in Thermo Fisher Scientific by 45.1% in the third quarter. Wealthfront Advisers LLC now owns 22,385 shares of the medical research company’s stock worth $10,857,000 after purchasing an additional 6,954 shares during the period. Hopwood Financial Services Inc. raised its holdings in Thermo Fisher Scientific by 9.1% during the 3rd quarter. Hopwood Financial Services Inc. now owns 239 shares of the medical research company’s stock worth $116,000 after purchasing an additional 20 shares during the last quarter. Finally, Centerpoint Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 1.9% in the 3rd quarter. Centerpoint Advisors LLC now owns 2,015 shares of the medical research company’s stock valued at $977,000 after purchasing an additional 38 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on TMO. The Goldman Sachs Group began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, December 9th. They issued a “buy” rating and a $685.00 price objective on the stock. Argus raised their price target on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. TD Cowen cut their target price on Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating on the stock in a research note on Friday, January 30th. Leerink Partners upped their price target on Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a research note on Wednesday, October 22nd. Finally, Wells Fargo & Company set a $683.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $633.68.

Insider Transactions at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 1,058 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $588.26, for a total transaction of $622,379.08. Following the completion of the transaction, the vice president directly owned 13,087 shares of the company’s stock, valued at $7,698,558.62. This trade represents a 7.48% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Michael D. Shafer sold 10,725 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the transaction, the executive vice president owned 18,731 shares of the company’s stock, valued at $11,238,600. The trade was a 36.41% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 114,292 shares of company stock worth $66,518,754. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $546.77 on Tuesday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.53 and a current ratio of 1.89. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The company’s 50 day moving average price is $589.99 and its two-hundred day moving average price is $543.92. The company has a market capitalization of $205.43 billion, a P/E ratio of 30.82, a price-to-earnings-growth ratio of 3.13 and a beta of 0.93.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.45 by $0.12. The company had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The firm’s revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $6.10 earnings per share. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share repurchase plan on Thursday, November 6th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board of directors believes its stock is undervalued.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.